| Patient | Alan Turing |
|---|---|
| Date of birth | 1912-06-23 |
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
| Document date | 2026-11-01 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent. Concerns: Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners; Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
| Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1953-06-09 | active | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth up to three times a day with food for no more than 5 days | One tablet up to three times a day with food, for no more than 5 days | Oral route | 1953-08-25 to 1953-08-30 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Scrotal ultrasound for gynecomastia workup: testes about 15 mL each, homogeneous, no mass; no varicocele | 1953-04-28 to 1953-04-28 | completed | S |
| Advance care planning conversation, about 20 minutes | 1953-10-20 to 1953-10-20 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1952-10-14 | Influenza vaccine, 1952-1953 season | completed | S |
| 1948-05-11 | Tdap vaccine | completed | S |
| 1953-10-20 | Influenza vaccine, 1953-1954 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 31 March 1952 | Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecency | D (CLM-0003, CLM-0004) |
| 1952 | Breast growth attributed to the hormone treatment, which he is known to have mentioned once | D (CLM-0005) |
| November 1952 | Decided to see a psychiatrist again and began Jungian analysis | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners | active | S |
| Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to | active | S |
Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1953-10-20; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 1953-10-06; Total score [AUDIT-C] 2 on 1953-10-20; Testosterone [Mass/volume] in Serum or Plasma 536 on 1953-10-06; Estradiol (E2) [Mass/volume] in Serum or Plasma 24 on 1953-10-06; Lutropin [Units/volume] in Serum or Plasma 4.8 on 1953-08-04; Follitropin [Units/volume] in Serum or Plasma 5.2 on 1953-08-04; Sex hormone binding globulin [Moles/volume] in Serum or Plasma 88 on 1953-04-14; Prolactin [Mass/volume] in Serum or Plasma 12.4 on 1953-06-09; Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma 1 on 1953-04-14; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 2.6 on 1953-04-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1953-04-14; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1953-04-14; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1953-04-14; Creatinine [Mass/volume] in Serum or Plasma 0.96 on 1953-04-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M 102 on 1953-04-14; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1953-04-14; Hemoglobin [Mass/volume] in Blood 14.4 on 1953-08-04; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 1953-10-06; Cholesterol [Mass/volume] in Serum or Plasma 182 on 1953-10-20; Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 on 1953-10-20; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 104 on 1953-10-20; Triglyceride [Mass/volume] in Serum or Plasma 80 on 1953-10-20 [S]
Strengths and supports: Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | resolved | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
| Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolved | resolved | confirmed | S93.401A | S — Synthetic sprain at an unscheduled visit, chosen to teach the Ottawa ankle rules and how to protect a depression plan that relies on running; it does not echo any documented injury. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 15 | {score} | S | ||
| 1953-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 1953-04-14 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 1953-04-14 | Testosterone [Mass/volume] in Serum or Plasma | 112 | ng/dL | 264-916 ng/dL | Low | S |
| 1953-04-14 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 148 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 1953-04-14 | Lutropin [Units/volume] in Serum or Plasma | 0.3 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
| 1953-04-14 | Follitropin [Units/volume] in Serum or Plasma | 0.4 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Low | S |
| 1953-04-14 | Sex hormone binding globulin [Moles/volume] in Serum or Plasma | 88 | nmol/L | 16.5-55.9 nmol/L | High | S |
| 1953-04-14 | Prolactin [Mass/volume] in Serum or Plasma | 21.6 | ng/mL | 4-15.2 ng/mL | High | S |
| 1953-04-14 | Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma | 1 | m[IU]/mL | <=3 m[IU]/mL | Normal | S |
| 1953-04-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | <=8.3 ng/mL | Normal | S |
| 1953-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 1953-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 1953-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1953-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1953-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1953-04-14 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1953-04-14 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1953-04-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 1953-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 1953-04-28 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 46 | pg/mL | 7.6-42.6 pg/mL | High | S |
| 1953-04-28 | Lutropin [Units/volume] in Serum or Plasma | 0.9 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Low | S |
| 1953-06-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 1953-06-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 1953-06-09 | Testosterone [Mass/volume] in Serum or Plasma | 238 | ng/dL | 264-916 ng/dL | Low | S |
| 1953-06-09 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 26 | pg/mL | 7.6-42.6 pg/mL | Normal | S |
| 1953-06-09 | Lutropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Normal | S |
| 1953-06-09 | Follitropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Normal | S |
| 1953-06-09 | Prolactin [Mass/volume] in Serum or Plasma | 12.4 | ng/mL | 4-15.2 ng/mL | Normal | S |
| 1953-06-09 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1953-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1953-08-04 | Testosterone [Mass/volume] in Serum or Plasma | 452 | ng/dL | 264-916 ng/dL | Normal | S |
| 1953-08-04 | Lutropin [Units/volume] in Serum or Plasma | 4.8 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Normal | S |
| 1953-08-04 | Follitropin [Units/volume] in Serum or Plasma | 5.2 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Normal | S |
| 1953-08-04 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1953-10-06 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1953-10-06 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 1953-10-06 | Testosterone [Mass/volume] in Serum or Plasma | 536 | ng/dL | 264-916 ng/dL | Normal | S |
| 1953-10-06 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 24 | pg/mL | 7.6-42.6 pg/mL | Normal | S |
| 1953-10-06 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | 30-100 ng/mL | Normal | S |
| 1953-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1953-10-20 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 1953-10-20 | Cholesterol [Mass/volume] in Serum or Plasma | 182 | mg/dL | <=199 mg/dL | Normal | S |
| 1953-10-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 62 | mg/dL | >=40 mg/dL | Normal | S |
| 1953-10-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 | mg/dL | <=129 mg/dL | Normal | S |
| 1953-10-20 | Triglyceride [Mass/volume] in Serum or Plasma | 80 | mg/dL | <=149 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-04-14 | Body height | 178 | cm | S |
| 1953-04-14 | Body weight | 71.4 | kg | S |
| 1953-04-14 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1953-04-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1953-04-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1953-04-14 | Heart rate | 64 | /min | S |
| 1953-04-14 | Respiratory rate | 14 | /min | S |
| 1953-04-14 | Body temperature | 36.6 | Cel | S |
| 1953-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-04-28 | Body height | 178 | cm | S |
| 1953-04-28 | Body weight | 71 | kg | S |
| 1953-04-28 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1953-04-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1953-04-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1953-04-28 | Heart rate | 62 | /min | S |
| 1953-04-28 | Respiratory rate | 14 | /min | S |
| 1953-04-28 | Body temperature | 36.5 | Cel | S |
| 1953-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-06-09 | Body height | 178 | cm | S |
| 1953-06-09 | Body weight | 70.1 | kg | S |
| 1953-06-09 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 1953-06-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1953-06-09 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1953-06-09 | Heart rate | 58 | /min | S |
| 1953-06-09 | Respiratory rate | 14 | /min | S |
| 1953-06-09 | Body temperature | 36.6 | Cel | S |
| 1953-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-08-04 | Body height | 178 | cm | S |
| 1953-08-04 | Body weight | 69.3 | kg | S |
| 1953-08-04 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1953-08-04 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1953-08-04 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1953-08-04 | Heart rate | 60 | /min | S |
| 1953-08-04 | Respiratory rate | 14 | /min | S |
| 1953-08-04 | Body temperature | 36.7 | Cel | S |
| 1953-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-10-06 | Body height | 178 | cm | S |
| 1953-10-06 | Body weight | 68.6 | kg | S |
| 1953-10-06 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 1953-10-06 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1953-10-06 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1953-10-06 | Heart rate | 54 | /min | S |
| 1953-10-06 | Respiratory rate | 14 | /min | S |
| 1953-10-06 | Body temperature | 36.6 | Cel | S |
| 1953-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-08-25 | Body height | 178 | cm | S |
| 1953-08-25 | Body weight | 69 | kg | S |
| 1953-08-25 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1953-08-25 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1953-08-25 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1953-08-25 | Heart rate | 70 | /min | S |
| 1953-08-25 | Respiratory rate | 14 | /min | S |
| 1953-08-25 | Body temperature | 36.7 | Cel | S |
| 1953-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1953-10-20 | Body height | 178 | cm | S |
| 1953-10-20 | Body weight | 68.5 | kg | S |
| 1953-10-20 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 1953-10-20 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1953-10-20 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1953-10-20 | Heart rate | 54 | /min | S |
| 1953-10-20 | Respiratory rate | 14 | /min | S |
| 1953-10-20 | Body temperature | 36.6 | Cel | S |
| 1953-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1953-04-14 | New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent | finished | S |
| 1953-04-28 | Two-week follow-up with endocrinology consultation and scrotal ultrasound | finished | S |
| 1953-06-09 | Eight-week review of hormone recovery and depression treatment | finished | S |
| 1953-08-04 | Sixteen-week review of hormone recovery and depression treatment | finished | S |
| 1953-10-06 | Six-month review of gynecomastia and depression in continuation treatment | finished | S |
| 1953-08-25 | Same-day sick visit for a right ankle sprain | finished | S |
| 1953-10-20 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given | completed | GL-APA-SM-2021, GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 | S |
| Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 | S |
| Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgery | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 | S |
| Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 | S |
| Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018, GL-ES-OSTEO-MEN-2012 | S |
| Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks | completed | GL-MDD-2022, GL-CMID-2026, GL-APA-SM-2021 | S |
| Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026 | S |
| Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers | completed | GL-CDC-STI-2021, GL-USPSTF-PREP-2023, GL-APA-SM-2021 | S |
| Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated | completed | GL-APA-SM-2021 | S |
| Add bupropion XL 150 mg each morning, chosen by him after an informed discussion of options and side effects; nurse telephone check at two weeks; PHQ-9 and blood pressure at each visit | completed | GL-CMID-2026, GL-MDD-2022 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy | 1953-08-04 | completed | Testosterone 452 ng/dL with normal LH and FSH at sixteen weeks | S |
| Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him | 1953-10-06 | active | Tenderness gone by six months; small residual glandular tissue; watchful waiting to twelve months | S |
| Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5) | 1953-10-06 | completed | PHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six months | S |
| Back to running about 40 km a week and changing at his club again | 1953-10-06 | completed | Running 40 km a week and back with the club by six months | S |
Structured synthetic safety assessment on 1953-04-14: current ideation absent, intent absent, plan absent. Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, and a two-week follow-up [S]